INSL4 Inhibitors
INSL4 Inhibitors are compounds that either directly impede the kinase activity of receptors associated with the insulin and IGF signaling pathways or obstruct downstream signaling events. These molecules are crucial since INSL4, being a member of the insulin family, can potentially engage in similar signaling cascades. For instance, the inhibitors Wortmannin and LY294002, which are potent PI3K antagonists, are capable of inhibiting the PI3K-Akt pathway, a pivotal route in insulin signaling. By blocking this route, the cellular responses influenced by INSL4 can be significantly diminished.
Further, a cluster of compounds in this category is typified by their ability to deter the activation of the insulin receptor (InsR) and the insulin-like growth factor-1 receptor (IGF-1R). AG1024, and BMS-754807 are prime examples of this class. Their function is integral as they can curtail the primary steps in the INSL4 signaling mechanism, rendering downstream events inactive.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent phosphoinositide 3-kinase (PI3K) inhibitor. Can inhibit downstream signaling from INSL4 by preventing activation of the PI3K-Akt pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor. Prevents the activation of the PI3K-Akt pathway which is potentially influenced by INSL4. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Inhibitor of Src family kinases. Can suppress tyrosine phosphorylation events downstream of insulin and IGF receptors. | ||||||
AG 1024 | 65678-07-1 | sc-205907 | 1 mg | $107.00 | 22 | |
A selective IGF-1R tyrosine kinase inhibitor. Can prevent IGF-1R activation and its subsequent signaling. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
Dual inhibitor of PI3K and mTOR. Can hinder the signaling cascade that INSL4 might engage in. | ||||||
BMS-754807 | 1001350-96-4 | sc-507396 | 5 mg | $304.00 | ||
Dual inhibitor for IGF-1R and InsR, can inhibit potential INSL4 downstream signaling by blocking these receptors. | ||||||
NVP-AEW541 | 475489-16-8 | sc-507395 | 5 mg | $285.00 | ||
A selective IGF-1R inhibitor. Prevents activation of pathways influenced by INSL4. | ||||||
PQ401 | 196868-63-0 | sc-221738 | 10 mg | $146.00 | ||
Specific inhibitor of IGF-1R tyrosine kinase. Obstructs downstream signaling from receptors potentially activated by INSL4. | ||||||
HNMPA-(AM)3 | 120944-03-8 | sc-221730 | 5 mg | $190.00 | 12 | |
Insulin receptor inhibitor. Can block the insulin receptor, potentially influencing INSL4 action. | ||||||
GSK1904529A | 1089283-49-7 | sc-507398 | 10 mg | $321.00 | ||
Potent inhibitor of IGF-1R and InsR, can block both receptors and hamper downstream signaling. | ||||||